Vents MagaZine Music and Entertainment Magazine
Related Articles
Dr. Jeff Geschwind has distinguished himself in the rapidly changing world of medical science. This is evident from his exceptional Google Scholar H-index of 84 which reflects the impact of his almost 300 scientific manuscripts that have been published to date. He is clearly an innovator and is considered one of the founders of interventional oncology as a new field of medicine. His outstanding accomplishments, dedication to clinical excellence and recent undertakings have made him a pioneer of interventional radiology and radiology more generally. His extensive body of work in image-guided therapy and imaging sciences has profoundly influenced the field as reflected by his H-index. His research helped establish treatments for patients with liver cancer that have become the new standards in cancer therapy. Dr. Geschwind’s pioneering work also paved the way to novel approaches in the fight against liver cancer. This article will cover various aspects of Dr. Geschwind’s distinguished career, thus giving the reader a full picture of its impact.
A Visionary Clinician-Scientist
Jeff Geschwind developed an interest in medicine and science through his early love of biology. After having attended the University of Pennsylvania to ease his transition into a new life in the United States from France, he earned his medical degree from Boston University School of Medicine and completed his residency training in Diagnostic Radiology at the University of California at San Francisco as a Resident-Scholar sponsored by the National Institutes of Health (NIH) which allowed him to dedicate a year of his residency to research. During that year, he published many scientific manuscripts, earned his first research award and more importantly, learned how to manage and run a research laboratory. He then pursued his fellowship training in Vascular and Interventional Radiology at the Johns Hopkins University School of Medicine before joining the faculty as an Assistant Professor. Shortly after, he was appointed the Director of the Division of Vascular and Interventional Radiology and a few years later, he was promoted to Professor of Radiology, Surgery, and Oncology at the Johns Hopkins University School of Medicine.
It is during his time at Johns Hopkins that Dr. Geschwind helped create the field of interventional oncology, first by co-organizing the first conference in the US as “Innovations in Cancer Therapy” and then subsequently as the first international conference dedicated to interventional oncology in London, United Kingdom in 2005, known as the World Conference on Interventional Oncology before becoming the official meeting of the newly formed Society of Interventional Oncology, for which he served as its first President. In addition, he co-edited the first textbook on interventional oncology published by Cambridge University Press in 2008. As a result, Dr. Geschwind is considered a pioneer and father of the field of Interventional Oncology, now considered the fourth pillar of oncology (along with medical, surgical and radiation). His extraordinary reputation as a clinician and scientist led him to co-edit the most prestigious book in interventional radiology, namely Abram’s Angiography, considered to be the textbook of reference in interventional radiology.
Dr. Geschwind is recognized internationally as an expert and key opinion leader in liver cancer, both for his remarkable clinical expertise and scientific contributions. He was the lead or co-investigator on more than 50 clinical trials testing innovative treatments for patients with liver cancer funded by pharmaceutical companies, foundations and/or the NIH. Some of these trials were care changing. He also received multiple patents for research on a new promising drug that targets a specific pathway in cancer cells, which allowed him to create a company based on this discovery. The fact that he has been at the forefront of over fifty clinical trials investigating innovative treatments for liver cancer patients not only shows his dedication to improving patient care but also makes him a major driver of groundbreaking medical breakthroughs. Dr. Geschwind’s clinical and research contributions have transformed the way people view interventional oncology and also influenced future directions in clinical research and patient care.
After an illustrious academic career, Dr. Geschwind joined the largest interventional radiology Office Based Laboratory practice in the US with the goal of creating an avenue for patients to access cutting edge Interventional Oncology procedures. These outpatient Interventional Oncology Centers contribute to improving the lives of thousands of cancer patients while decreasing costs dramatically.
International Recognition and Awards
As a testament to his scientific success and accomplishments, Dr. Geschwind has received numerous national and international awards throughout his career including among others the Annual Memorial Award from the Association of University Radiologists, the Alexander Margulis Award for Excellence in Research, the Society of Interventional Radiology Gary Becker Young Investigator Award, the American Roentgen Ray Society Fellowship Award, the American Society of Clinical Oncology Merit Award, the Boston University School of Medicine and the University of California San Francisco Department of Radiology Alumni Award, the Ernest Ring Academic Development Program from the Society of Interventional Radiology and the Wilhelm Conrad Roentgen Honorary Award from the European Society of Radiology. Most recently, he was recognized by the Marquis Who’s Who organization for his clinical and scientific accomplishments during his career and awarded the Albert Nelson Marquis Lifetime Achievement Award. In 2012, he was inducted into the Academy of Radiology Research from the Radiology Society of North America, the highest recognition for radiologists. This latter achievement marked a significant milestone in his career as it established him as one of the most prominent physician-scientists in the field of radiology.
Academic Impact
As already mentioned, Dr. Jeff Geschwind is more than a clinician. Under Dr. Geschwind’s leadership during his tenure at Johns Hopkins School of Medicine, the Division of Vascular and Interventional Radiology underwent massive growth, both in terms of clinical activities and research. He founded the Center of Oncologic Interventions, which utilized revolutionary imaging technology in collaboration with Philips Health Care (partly supported by funding from the NIH) to visualize tumors, target them with exquisite precision and as a result treat them more effectively. After having received an RO1 grant from the NIH in 2005, he also established his research laboratory focusing on cancer therapeutics that specifically block tumor glycolysis in cancer cells. In 2008, he received a $1.4 million philanthropic donation to further support this research. In 2009, he founded a company based on this technology and raised $5M towards the goal of starting Phase I clinical trials for liver and pancreas cancer. He is recognized worldwide as a key opinion leader in the field of liver cancer (hepatocellular carcinoma) and has received numerous foundation, industry and federal grants for his research in the field.
His research accomplishments translated into nearly 300 published manuscripts in some of the most prestigious scientific journals and a Google Scholar H-index of 84, which is one of the highest in the entire field of radiology. In addition, he has served on the editorial board of many scientific journals including Radiology, Cardiovascular and Interventional Radiology, the Journal of Vascular and Interventional Radiology, Anticancer Research and has been a reviewer for many additional journals including Lancet, Cancer Research, Hepatology and the Journal of Clinical Oncology. He recently joined the editorial board of the journals “Diagnostics”, “Gastroenterology Insights” and “Frontiers in Oncology”.
Because of the significance and impact of his clinical and scientific contributions, Dr. Geschwind has been a sought-after speaker. Indeed, he was visiting professor and has given numerous lectures and keynote speeches including named lectures at various prestigious institutions such as (among others) the National Institutes of Health (NIH), Memorial Sloan Kettering Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, the University of Michigan, Georgetown University, Brown University, Yonsei University, Seoul National University, Malaysia Cancer Center, and the Chinese University of Hong Kong. His clinical excellence in interventional radiology and oncology with a special expertise in treating patients with liver cancer led to him being recognized by US News and World Report as a Top Doctor. He is a diplomate of the American Board of Radiology since 1998.
Recent Endeavors
Since leaving his chairmanship position at Yale and moving on from his career in academic medicine, Dr. Geschwind has embarked on a new career that includes clinical practice in an outpatient interventional radiology clinic (see above), a medical directorship in oncology and image-guided therapy for a clinical research organization (CRO) where he provides expert advice in clinical trials and a medical advisory position for a biotech company with an extremely promising image-guided technology called histotripsy to treat cancer non-invasively.
As part of his work for the CRO, Dr. Geschwind was involved in various clinical trials including cryoablation for breast cancer, endobronchial therapy for lung cancer, and intraarterial therapy using radioactive microspheres for liver cancer, thereby providing hope to patients suffering from these devastating diseases. His involvement in histotripsy which consists of non-invasive ultrasound-guided therapy for liver and kidney cancers confirms his unending commitment to prescient therapeutic methods that may radically impact cancer therapy. As an interventional oncologist, Dr. Jeff Geschwind stands as the epitome of creativity and perseverance, steering the field towards a new era and giving hope to many patients worldwide.
Conclusion: A Legacy of Excellence
In summary, Dr. Jeff Geschwind’s contributions have been outstanding, and his influence on the field of interventional oncology has been far reaching. Beyond his many scientific manuscripts, research accomplishments and global recognition, it is perhaps Dr. Geschwind’s commitment to creating a supportive environment for his trainees and mentees in his various academic positions and research laboratory that will be remembered as his most meaningful legacy.
